文献速递胸部肿瘤

肿瘤内CD8+/FoxP3+双阳性T细胞密度预测局部晚期N2非小细胞肺癌放化疗疗效

Chemoradiotherapy efficacy is predicted by intra-tumour CD8+/FoxP3+ double positive T cell density in locally advanced N2 non-small-cell lung carcinoma.
PubMed 文献 · Eur J Cancer · 2020-06-28

该回顾性研究分析了113例接受化疗和放疗的III期N2非小细胞肺癌患者肿瘤样本,通过多重原位染色检测CD8、FoxP3、PD-L1和细胞角蛋白。结果显示肿瘤内CD8+ T细胞高密度与总生存期和无病生存期相关,而CD8+/FoxP3+双阳性T细胞密度是全人群总生存期的最佳预测因子,提示放疗疗效需要预先存在的肿瘤内免疫。

要点

  • 肿瘤内CD8+ T细胞高密度与PORT患者OS和DFS显著相关。
  • CD8+/FoxP3+双阳性T细胞密度是全人群OS的独立预测因子。
  • 肿瘤细胞PD-L1中等表达(TPS 1-49%)与PORT患者更高生存相关。

核心结论

  • 肿瘤内CD8+ T细胞特别是CD8+/FoxP3+双阳性T细胞密度可预测III期N2非小细胞肺癌患者生存,提示需要预先存在的肿瘤内免疫来介导放疗作用。
  • CD8+/FoxP3+细胞密度在多变量分析中是患者生存的最佳预测因子,可能作为放疗疗效的生物标志物。

研究设计与样本

  • 回顾性分析2002年至2015年同一放疗科收治的113例接受化疗和放疗的N2-NSCLC患者肿瘤样本和临床数据。
  • 其中89例为术后放疗(PORT),24例为未手术的根治性放化疗(DRC)。
  • 采用原位多重染色检测CD8、FoxP3、PD-L1和细胞角蛋白,并与临床数据和生存进行相关性分析。

主要发现

  • 在PORT组中,CD8+ T细胞高密度与OS相关(p=0.04,HR=1.93 [0.99-3.78]),与DFS相关(p=0.003,HR=2.42 [1.31-4.47])。
  • 在全人群中,CD8+/FoxP3+双阳性细胞高密度与OS相关(p=0.01,HR=1.97 [1.11-3.48])。
  • 在PORT组中,CD8+/FoxP3+双阳性细胞高密度与OS相关(p=0.05,HR=1.92 [0.98-3.74]),与PFS相关(p=0.03,HR=1.83 [1.03-3.23]),但在DRC组未达到显著性。
  • 在PORT组中,肿瘤细胞PD-L1中等表达(TPS=1-49%)与更高的生存相关。

临床怎么用

  • 肿瘤内CD8+/FoxP3+双阳性T细胞密度可作为接受放化疗的III期N2非小细胞肺癌患者的预后生物标志物。
  • 检测肿瘤内CD8+ T细胞和CD8+/FoxP3+双阳性T细胞密度可能有助于识别从放疗中获益更多的患者。

局限性

  • 本研究为回顾性分析,样本量有限(共113例,DRC组仅24例)。
  • 未在DRC组中观察到CD8+/FoxP3+双阳性细胞密度与生存的显著相关性,可能受样本量限制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Radiotherapy is a standard of care for locally advanced stage III N2 non-small-cell lung carcinoma (NSCLC) combined with surgery/chemotherapy. Radiotherapy is hypothesised to induce tumour immunogenic cell death, to release neoantigen resulting in intra-tumoural immune infiltration and abscopal effect. Conversely, it has not been demonstrated if immune cells are necessary to drive radiotherapy efficacy and predict patient's survival. PATIENTS AND METHODS: We retrospectively analysed tumour samples and clinical data from 113 patients, 89 resected (PORT) and 24 non-resected (DRC) N2-NSCLC treated with chemotherapy and radiotherapy (same radiotherapy department from 2002 to 2015). The immune environment was characterised with in situ multiplex staining (CD8, FoxP3, PD-L1 and cytokeratin) and correlated with clinical data and survival. RESULTS: High density of CD8+ T cells was associated with OS (p = 0.04, HR = 1.93 [0.99-3.78]) and DFS (p = 0.003, HR = 2.42 [1.31-4.47]) in the PORT. High density of CD8+/FoxP3+ double positive cells was associated with OS (p = 0.01, HR = 1.97 [1.11-3.48]) in the whole population, with OS (p = 0.05, HR = 1.92 [0.98-3.74]) and PFS (p = 0.03, HR = 1.83 [1.03-3.23]) in the PORT without reaching significance for the DRC. Intermediate PD-L1 expression in tumour cells (TPS = 1-49%) was associated with a higher survival in the PORT. CONCLUSIONS: Intra-tumoural CD8+ T cell and particularly CD8+/FoxP3+ double positive T cell densities predict survival in stage III N2-NSCLC suggesting the need for a pre-existing intra-tumour immunity to mediate the action of radiotherapy. Density of CD8+/FoxP3+ cells was the best predictor of patient's survival in multivariate analysis and could represent a biomarker of radiotherapy efficacy.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Boulle G, Velut Y, Mansuet-Lupo A, et al. Chemoradiotherapy efficacy is predicted by intra-tumour CD8+/FoxP3+ double positive T cell density in locally advanced N2 non-small-cell lung carcinoma. Eur J Cancer. 2020. PMID: 32610210. doi:10.1016/j.ejca.2020.04.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。